VUNO Showcases DeepCARS® at AACN NTI 2025, Highlighting AI-Driven Cardiac Arrest Risk Prediction
– Company engages U.S. critical care professionals with data-driven early warning solution
MARLBOROUGH, Mass., May 26, 2025 /PRNewswire/ -- VUNO, a global medical AI company, presented its flagship solution VUNO Med ® –DeepCARS ® at the 2025 National Teaching Institute & Critical Care Exposition (NTI), hosted by the American Association of Critical-Care Nurses (AACN), from May 19–21 at the Ernest N. Morial Convention Center in New Orleans.
DeepCARS is an AI-powered medical device that predicts an inpatient's risk of in-hospital cardiac arrest within the next 24 hours. By continuously analyzing patients' vital signs—such as blood pressure, heart rate, respiratory rate, and body temperature— the solution enables timely clinical intervention in general wards.
"Collaborating with AACN members has reaffirmed how DeepCARS can meaningfully contribute to both hospital efficiency and patient safety—empowering clinicians with timely insights that lead to proactive, life-saving care," said Robert Tingley, Vice President of Business Development at VUNO. "We sincerely thank the critical care community for their thoughtful engagement and valuable insight."
At AACN NTI 2025, VUNO's booth drew significant attention from clinical professionals, particularly members of Rapid Response Teams (RRTs) seeking innovative tools to detect patient deterioration earlier and respond more effectively. The VUNO team—including Robert Tingley, Andrew Abbring (Area Sales Director), and Tae Min Son (Director of Product Management)—engaged with healthcare stakeholders to better understand the needs and workflows of U.S. hospitals.
DeepCARS has been adopted across more than 48,000 hospital beds in South Korea, including 20 tertiary general hospitals, making it a critical component of routine care. In 2023, the solution received Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) and is currently undergoing the FDA 510(k) clearance process.
As the company strengthens its presence in the U.S. market, it continues to focus on working closely with healthcare providers to ensure successful integration into existing clinical workflows and environments.
About VUNO
Founded in Seoul in 2014, VUNO is a global medical AI company and the developer of the nation's first approved AI-powered medical device. Leveraging cutting-edge AI technology, VUNO analyzes a wide range of medical data—from bio signals such as ECG, respiratory rate and blood pressure to medical images including X-rays, CT scans, and fundus images—to predict critical events and support clinicians in decision-making. Committed to patient-centered innovation, VUNO strives to make high-quality healthcare accessible to everyone, worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
18 hours ago
- Korea Herald
ValueLabs Announces Strategic Pivot—Exclusively Offering Outcome-Based Engagements Globally
Company shifts away from Time & Materials contracts for all new clients, embracing outcome-driven, AI-powered delivery models. HYDERABAD, India, May 30, 2025 /PRNewswire/ -- ValueLabs, a global leader in Agentic AI Services, today announced a strategic pivot, transitioning fully away from traditional Time & Materials (T&M) contracts for new clients across all major markets. This milestone reinforces ValueLabs' commitment to outcomes, innovation, and its transformative Enterprise OS platform—AiDE®. As of today, all new engagements with ValueLabs will leverage outcome-based delivery models, including Managed Services (MSP), fixed-price engagements, productivity-linked pricing, and value-sharing agreements. This strategic shift aligns ValueLabs' incentives with clients, ensuring measurable business impact, predictable outcomes, and accelerated value realization. The decision comes on the heels of rapid adoption and widespread success of AiDE®, ValueLabs' proprietary Agentic AI platform. AiDE acts as an Enterprise Operating System, embedding autonomous AI agents into core enterprise workflows across software engineering, business operations, analytics, and strategic workflows, transforming clients into AI-native enterprises. Speaking about this strategic pivot, Arjun Rao, Founder and Chairman of ValueLabs, said, "The era of billing hours is behind us. Our clients don't just want work done—they want measurable outcomes, faster innovation, and business results that matter. With AiDE, we have the confidence, capabilities, and credibility to deliver exactly that. This shift isn't merely operational; it redefines how technology partners add real value in the Agentic Era." Sam Alva, CEO of ValueLabs, reinforced the strategic vision: "We've already proven that AiDE-driven delivery significantly accelerates outcomes and improves productivity. We are now aligning our commercial models to reflect this reality. Outcome-based engagements ensure our success is directly tied to our clients' outcomes. It's a win-win approach powered by our platform-led, Service-as-Software model—where AiDE transforms everything, everywhere, all at once." This announcement positions ValueLabs at the forefront of a fundamental industry shift—from traditional service delivery, towards innovative, outcome-aligned partnerships. Clients from across verticals like Commerce, Healthcare, Insurance, and Travel have already experienced substantial benefits from this model, achieving tangible business impacts including increased speed-to-market, improved operational efficiencies, and measurable financial returns. About ValueLabs ValueLabs & AiDE®: Enterprise OS of the Agentic Era From Engineering to Everything—custom agents powering AI-native enterprises. Founded in 1997, ValueLabs is a global Agentic AI Services firm helping enterprises reinvent themselves as AI-native organizations. At the core of this transformation is AiDE®—ValueLabs' proprietary platform and the Enterprise Operating System for the Agentic Era. AiDE integrates custom-built autonomous AI agents seamlessly across software engineering, business operations, analytics, and strategic workflows. With over 7,000 professionals serving more than 300 enterprise clients globally, ValueLabs leverages AiDE and innovative Service-as-Software delivery models to unlock productivity, agility, and sustainable competitive advantage.
Korea Herald
21 hours ago
- Korea Herald
Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful efficacy signals in a subgroup of participants with slow disease progression in its recently completed Phase 3 trial. The therapy also showed consistent reductions in neurofilament light chain (NfL) levels — a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen — supporting its potential to pursue a similar regulatory pathway. Developed by South Korean biotech company CorestemChemon (KOSDAQ: 166480), Neuronata-R® utilizes MSCs derived from a participant's own bone marrow to modulate inflammation, protect motor neurons, and alter the neurodegenerative microenvironment through paracrine signaling. ALS, a rare and fatal disease with no cure, remains one of the most urgent areas of unmet medical need. Neuronata-R® aims to address the disease's complex pathology by leveraging the therapeutic potential of autologous MSCs. In December 2024, CorestemChemon announced topline results from the ALSummit trial (NCT04745299), noting that the study did not meet its primary endpoint — a combined assessment of function and survival known as CAFS — in the overall patient population. However, a post hoc analysis conducted after the completion of the trial and full data collection revealed significant clinical improvements in a subgroup of patients with slower disease progression. To discuss these findings, the company plans to meet with the U.S. Food and Drug Administration (FDA) later this year to discuss these findings, with the aim of submitting a biologics license application by the end of 2025 and potentially securing accelerated approval by mid-2026. Subgroup Analysis Supports Targeted Efficacy The final Clinical Study Report (CSR) confirmed that Neuronata-R® demonstrated statistically significant improvements in key efficacy endpoints among participants with slow disease progression. Recognizing the potential efficacy of Neuronata-R® in early-stage ALS, CorestemChemon stratified participants into slow and fast progressors. Among slow progressors, Neuronata-R® showed statistically significant improvements across multiple measures — including the primary composite endpoint, CAFS (Combined Assessment of Function and Survival), functional outcomes assessed by ALSFRS-R scores, and respiratory function measured by slow vital capacity (SVC). Notably, the five-dose treatment arm (Group 2) demonstrated statistically significant improvement in ALSFRS-R scores beginning at Month 9 post-treatment — one month earlier than the two-dose arm (Group 1), which reached significance at Month 10. This final CSR also included full analyses of CAFS and SVC, which had not been previously disclosed. While CAFS served as the trial's primary efficacy endpoint, SVC is recognized as a clinically meaningful measure of respiratory decline in ALS. At Month 6, participants in Group 1 receiving Neuronata-R® showed a statistically significant improvement in CAFS (LS Mean 20.95 vs 13.66; 95% CI; p<0.024) compared with placebo. Group 2 also showed improvement (LS Mean 24.78 vs 17.92; 95% CI; p<0.041). In Group 2, significant divergence in SVC compared to the control group emerged from Month 8 post-treatment, suggesting a potential effect in delaying disease progression. NfL Biomarker Reduction Mirrors Regulatory Precedent CorestemChemon also highlighted the reduction in NfL levels — a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen. In both the two-dose (Group 1) and five-dose (Group 2) arms, NfL levels consistently declined over time. Notably, in Group 2, NfL levels were significantly lower than placebo at both Month 4 and Month 10, suggesting a potential dose-dependent effect. The consistency between the company's internal analysis and validation by an independent CRO strengthens the reliability of the dataset, which has been incorporated into the final CSR. "This subgroup analysis lends strong support to a biomarker-driven approval strategy," a company official said. "The consistency of our internal analysis with external CRO validation adds credibility to the dataset and provides a concrete basis for regulatory discussions with the MFDS." Regulatory Pathway Toward Accelerated Approval The company views these findings as strategically significant, particularly in light of their alignment with the precedent set by Tofersen, where the FDA granted accelerated approval based on NfL reduction rather than survival benefit — a pathway CorestemChemon now seeks to pursue. The company plans to request a Pre-BLA or Type C meeting with the FDA in Q3 2025, with the goal of submitting a biologics license application by Q4 2025 and targeting regulatory approval by mid-2026. CorestemChemon will finalize its submission package in collaboration with a global CRO and actively engage with regulatory agencies to pursue worldwide market entry for Neuronata-R®. Innovative Stem Cell Therapy Neuronata-R® uniquely addresses the complex mechanisms of ALS by leveraging MSCs derived from the patient's own bone marrow. These cells exert anti-inflammatory and immunomodulatory effects, protect motor neurons, and, through paracrine signaling, secrete trophic factors, cytokines, and extracellular vesicles that modulate the microenvironment and reduce neuroinflammation. By targeting these underlying pathological processes, Neuronata-R ® is designed to interrupt the neurodegenerative cascade. About Neuronata-R® Neuronata-R® (Lenzumestrocel), developed and commercialized by CorestemChemon Inc. (KOSDAQ: 166480), is an autologous MSC therapy for ALS patients. The company began ALS research in 2002 and obtained MFDS approval for Neuronata-R® in 2014. To date, it has been administered to more than 400 commercial patients and 190 clinical trial participants with no treatment-related serious adverse events reported. Neuronata-R® holds Orphan Drug Designation from both the U.S. FDA (2018) and the EMA (2019). CorestemChemon completed a Phase 2 trial (NCT01363401) in 2014 and its Phase 3 trial (NCT04745299) in 2024; the final CSR has been submitted to the MFDS.
Korea Herald
3 days ago
- Korea Herald
Casio to Release New MT-G Featuring an Original Frame Co-Created by Humans and AI
Newly Developed Structure Fusing Different Materials TOKYO, May 27, 2025 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the latest addition to the G-SHOCK brand of shock-resistant watches: the MTG-B4000. This new timepiece features a distinctive frame developed in a process of collaboration between human designers and AI technology. The MTG-B4000 joins the MT-G line of timepieces, all of which utilize a unique construction that makes the most of the properties of both metal and resin. The new MTG-B4000 is a shock-resistant watch featuring a distinctive frame that was developed in a process of collaboration between human designers and generative AI and uses a combination of different materials. For the first time in a Casio consumer timepiece, generative AI technology was integrated into the development process. In pursuit of innovative craftsmanship, designers employed this advanced technology as a creative tool to explore new design possibilities and conquer the challenge of realizing a complex, unconventional structure which would have been difficult to achieve using traditional methods. Starting with design proposals from human designers, AI conducted load simulations using decades of accumulated data on shock-resistant construction for G-SHOCK. It then proposed optimal structural configurations by evaluating factors such as structural strength, material characteristics, and machinability. These AI-generated designs were refined through repeated testing and adjustments by skilled human hands, resulting in a frame that delivers the G-SHOCK signature ruggedness with a distinctive, unconventional aesthetic only achievable through AI collaboration. A new approach was also introduced by integrating the band connection parts into the frame. This allows the frame to directly absorb loads applied to the band, reducing impact on the center case and further enhancing shock resistance. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. Any use of such marks and logos by Casio Computer Co., Ltd. is under license.
